Abstract
Background
To explore correlations between the clinical attributes of secondary bladder cancer and brachytherapy, we retrospectively reviewed our institutional database on patients with localized prostate cancer who underwent low-dose-rate brachytherapy (LDR-BT) or high-dose-rate brachytherapy (HDR-BT) with or without external beam radiation therapy (EBRT) or radical prostatectomy (RP).
Methods
From October 2003 to December 2014, 2551 patients with localized prostate cancer were treated at our institution. Of these, data on 2163 were available (LDR-BT alone: n = 953; LDR-TB with EBRT: n = 181; HDR-BT with EBRT: n = 283; RP without EBRT: n = 746). The times of secondary bladder cancer development subsequent to radical treatment, and their clinical characteristics, were studied.
Results
Age-adjusted Cox’s regression analyses indicated that brachytherapy did not significantly impact the incidence of secondary bladder cancer. However, the pathological characteristics of such cancer differed between patients treated via brachytherapy and RP without EBRT; invasive bladder cancer was more common in such patients.
Conclusion
The risk for secondary bladder cancer was not significantly increased after brachytherapy compared to non-irradiation therapy. However, brachytherapy patients exhibited a higher incidence of invasive bladder cancer. Therefore, meticulous follow-up is crucial for early detection and treatment of bladder cancer in such patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Wang J, Xia HH, Zhang Y et al (2021) Trends in treatments for prostate cancer in the United States, 2010–2015. Am J Cancer Res 11(5):2351–2368
Chrouser K, Leibovich B, Bergstralh E et al (2008) Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol 179(5 Suppl):S7-s11
Pawlish KS, Schottenfeld D, Severson R et al (1997) Risk of multiple primary cancers in prostate cancer patients in the Detroit metropolitan area: a retrospective cohort study. Prostate 33(2):75–86
Brenner DJ, Curtis RE, Hall EJ et al (2000) Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88(2):398–406
Moschini M, Zaffuto E, Karakiewicz PI et al (2019) External beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer: a population-based analysis. Eur Urol 75(2):319–328
Liauw SL, Sylvester JE, Morris CG et al (2006) Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys 66(3):669–673
Ozawa Y, Yagi Y, Nakamura K et al (2022) Secondary bladder cancer during long-term follow-up after iodine-125 permanent seed implantation for localized prostate cancer. Brachytherapy 21(4):451–459
Minami T, Fujita K, Hashimoto M et al (2023) External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy. World J Urol 41:1317–1321
Urabe F, Miki K, Kimura T et al (2022) Clinical significance of unfavorable findings in intermediate-risk prostate cancer patients for predicting treatment outcomes after contemporary, dose-escalated multimodal radiotherapy. Prostate 82(4):433–441
Urabe F, Kimura T, Sasaki H et al (2022) Prognostic value of PSA bounce after definitive radiotherapy revisited. Int J Clin Oncol 27(2):411–417
Urabe F, Kimura T, Sasaki H et al (2022) How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate cancer? Int J Clin Oncol 27(1):184–193
Imai Y, Urabe F, Iwatani K et al (2023) Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy. Int J Clin Oncol 28(5):698–706
Kadena S, Urabe F, Iwatani K, et al (2023) The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiation. Int J Clin Oncol (in press)
Yee DS, Shariat SF, Lowrance WT et al (2010) Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. J Urol 183(5):1751–1756
Kinoshita Y, Singh A, Rovito PM Jr et al (2004) Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer 3(2):83–86
Coyte A, Morrison DS, McLoone P (2014) Second primary cancer risk—the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study. BMC Cancer 14:272
Acknowledgements
The authors would like to thank Textchek for English language editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
About this article
Cite this article
Miyajima, K., Suzuki, H., Urabe, F. et al. Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancer. Int J Clin Oncol 28, 1200–1206 (2023). https://doi.org/10.1007/s10147-023-02383-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-023-02383-1